Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) EPS (Weighted Average and Diluted) (2016 - 2025)

United Therapeutics' EPS (Weighted Average and Diluted) history spans 17 years, with the latest figure at $7.69 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 23.83% year-over-year to $7.69; the TTM value through Dec 2025 reached $27.86, up 13.07%, while the annual FY2025 figure was $27.86, 13.07% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $7.69 at United Therapeutics, up from $7.15 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $7.69 in Q4 2025 and bottomed at $0.61 in Q1 2021.
  • The 5-year median for EPS (Weighted Average and Diluted) is $5.14 (2022), against an average of $4.87.
  • The largest annual shift saw EPS (Weighted Average and Diluted) plummeted 80.45% in 2021 before it surged 724.59% in 2022.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $2.38 in 2021, then grew by 11.34% to $2.65 in 2022, then surged by 63.4% to $4.33 in 2023, then soared by 43.42% to $6.21 in 2024, then grew by 23.83% to $7.69 in 2025.
  • Per Business Quant, the three most recent readings for UTHR's EPS (Weighted Average and Diluted) are $7.69 (Q4 2025), $7.15 (Q3 2025), and $6.39 (Q2 2025).